Cardiology Plus

OPINION
Year
: 2020  |  Volume : 5  |  Issue : 4  |  Page : 171--174

Warfarin or non-Vitamin K antagonist oral anticoagulants: Navigating the choice of oral anticoagulant drugs in the COVID-19 pandemic era


Heng Cai, Xin Zhou, Qing Yang 
 Department of Cardiology, Tianjin Medical University General Hospital, Tianjin, China

Correspondence Address:
Qing Yang
Department of Cardiology, Tianjin Medical University General Hospital, 154, Anshan Road, Heping District, Tianjin 300052
China

Emerging evidence indicates that thromboembolic complications are a key determinant of inhospital mortality of patients with COVID-19. Prophylactic anticoagulation therapy is an important component of inhospital management of patients with COVID-19. Considering that millions of patients worldwide are prescribed oral anticoagulation therapy, herein, we summarize the pros and cons of non-Vitamin K antagonist oral anticoagulants (NOACs) and warfarin, in terms of pharmacodynamics, and therapeutic efficacy and adverse effect monitoring in the context of the global pandemic of COVID-19. Despite a lack of evidence from high-quality randomized trials, an NOAC, rather than warfarin, would be a scientifically reasonable treatment option for patients with COVID-19 in the outpatient setting.


How to cite this article:
Cai H, Zhou X, Yang Q. Warfarin or non-Vitamin K antagonist oral anticoagulants: Navigating the choice of oral anticoagulant drugs in the COVID-19 pandemic era.Cardiol Plus 2020;5:171-174


How to cite this URL:
Cai H, Zhou X, Yang Q. Warfarin or non-Vitamin K antagonist oral anticoagulants: Navigating the choice of oral anticoagulant drugs in the COVID-19 pandemic era. Cardiol Plus [serial online] 2020 [cited 2021 Mar 5 ];5:171-174
Available from: https://www.cardiologyplus.org/article.asp?issn=2470-7511;year=2020;volume=5;issue=4;spage=171;epage=174;aulast=Cai;type=0